Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs S&P Global Inc (SPGI) Price & Performance

Moderna, Inc.Trade
S&P Global IncTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs S&P Global Inc — how do they compare? Moderna, Inc. trades at $63.7 (market cap $24.18B), while S&P Global Inc trades at $410.94 (market cap $120.48B). The key difference: S&P Global Inc is far larger — about 5× Moderna, Inc.'s market cap, and S&P Global Inc pays a 0.95% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

MRNASPGI
Market Cap
$24.18B$120.48B
Sector
HealthFinancials
52-Week High
$81.80$534.79
52-Week Low
$22.36$370.42
Enterprise Value
$20.33B$131.97B
Dividend Yield
0.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

S&P Global Inc

S&P Global (SPGI) trades at $410.26, down 0.17% on the day, with a bearish technical signal from moving averages and ADX. The company reported strong Q2 2026 earnings of $4.83 per share, beating estimates, and maintains robust profitability with a 30.54% net income margin. Recent news highlights expansion in AI and data collaborations, including integration with Microsoft 365 Copilot.

The outlook remains positive with 86% analyst buy ratings and a $523.20 consensus price target, implying significant upside. Risks include competitive pressures and reliance on financial market health. Revenue growth and strategic partnerships support long-term value, but investors should monitor execution against high expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About S&P Global Inc

S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.

Read more on SPGI